Mylan Pharmaceuticals

View All

Chemotherapy Induced Febrile Neutropenia Market
Chemotherapy Induced Febrile Neutropenia Market: High time to end the monopoly

A rich pipeline in the Chemotherapy Induced Febrile Neutropenia market with promising clinical pieces of evidence, CIFN market size is expected to increase drastically by 2030 A range of breakthroughs and series of medical advancements have significantly helped in dampening down the global burden of cancer, wh...

Find More

Celecoxib first Generic Approval to Teva and Mylan from FDA

On May 30, 2014, the U.S. Food and Drug Administration approved the first generic versions of Celebrex (celecoxib) capsules. Teva Pharmaceutical Industries received approval to market celecoxib capsules in 50 milligram, 100 mg, 200 mg, and 400 mg strengths, and has 180-day exclusivity on the 100 mg, 200 mg, and 400 ...

Find More